MMPs in the neuroretina and optic nerve: Modulators of glaucoma pathogenesis and repair?

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1953-1964

  De Groef, Lies ^a   Van Hove, Inge ^a   Dekeyster, Eline ^a   Stalmans, Ingeborg ^b   Moons, Lieve ^a  

^a SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^b KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cell therapy; Glaucoma; Matrix metalloproteinase; Neuroprotection; Regeneration

Indexed keywords

GELATINASE A; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; ILOMASTAT; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; KAINIC ACID; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MYELIN ASSOCIATED GLYCOPROTEIN; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; NITRIC OXIDE; PROTEOCHONDROITIN SULFATE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; AQUEOUS HUMOR; AQUEOUS HUMOR OUTFLOW; CELL TRANSPLANTATION; DISEASE COURSE; EXPERIMENTAL GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NERVE FIBER REGENERATION; NEUROPROTECTION; OPTIC NERVE; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; RETINA GANGLION CELL; REVIEW; TRABECULAR MESHWORK;

CELL THERAPY; GLAUCOMA; MATRIX METALLOPROTEINASE; NEUROPROTECTION; REGENERATION;

GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MATRIX METALLOPROTEINASES; OPTIC NERVE; RETINAL GANGLION CELLS;

EID: 84897127842     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13630     Document Type: Review

References (102)

1. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2010;41:271-290.
2. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res. 2007;85:2813-2823.
3. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol. 2007;8:221-233.
4. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8: 205-216.
5. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17: 463-516.
6. Miller JP, Holcomb J, Al-Ramahi I, et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron. 2010;67:199-212.
7. Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci. 2010;30: 15337-15357.
8. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005;6:931-944.
9. Fujioka H, Dairyo Y, Yasunaga K, Emoto K. Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem Res Int. 2012;2012:789083.
10. Milward EA, Fitzsimmons C, Szklarczyk A, Conant K. The matrix metalloproteinases and CNS plasticity: an overview. J Neuroimmunol. 2007;187:9-19.
11. Tonti GA, Mannello F, Cacci E, Biagioni S. Neural stem cells at the crossroads: MMPs may tell the way. Int J Dev Biol. 2009; 53:1-17.
12. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ. Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist. 2010;16:156-170.
13. Verslegers M, Lemmens K, Van Hove I, Moons L. Matrix metalloproteinase-2 and-9 as promising benefactors in development, plasticity and repair of the nervous system. Prog Neurobiol. 2013;105:60-78.
14. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
15. Calkins DJ, Horner PJ. The cell and molecular biology of glaucoma: axonopathy and the brain. Invest Ophthalmol Vis Sci. 2012;53:2482-2484.
16. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-1972.
17. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
18. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641-1648.
19. Bouhenni RA, Dunmire J, Sewell A, Edward DP. Animal models of glaucoma. J Biomed Biotechnol. 2012;2012: 692609.
20. Johnson TV, Tomarev SI. Rodent models of glaucoma. Brain Res Bull. 2010;81:349-358.
21. De Groef L, Van Hove I, Dekeyster E, Stalmans I, Moons L. MMPs in the trabecular meshwork: promising targets for future glaucoma therapies? Invest Ophthalmol Vis Sci. 2013; 54:7756-7763.
22. Agapova OA, Kaufman PL, Lucarelli MJ, Gabelt BT, Hernandez MR. Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. Brain Res. 2003;967:132-143.
23. Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia. 2001;33:205-216.
24. Webster L, Chignell AH, Limb GA. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res. 1999;68:91-98.
25. Smine A, Plantner JJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res. 1997;16:925-929.
26. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci. 2005;46:175-182.
27. Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem. 2002;277:47461-47468.
28. Santos ARC, Corredor RG, Obeso BA, et al. Beta1 integrinfocal adhesion kinase (FAK) signaling modulates retinal ganglion cell (RGC) survival. PLoS One. 2012;7:e48332.
29. Zhang X, Cheng M, Chintala SK. Optic nerve ligation leads to astrocyte-associated matrix metalloproteinase-9 induction in the mouse retina. Neurosci Lett. 2004;356:140-144.
30. Zhang X, Chintala SK. Influence of interleukin-1 beta induction and mitogen-activated protein kinase phosphorylation on optic nerve ligation-induced matrix metalloproteinase-9 activation in the retina. Exp Eye Res. 2004;78:849-860.
31. Zhang X, Sakamoto T, Hata Y, et al. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res. 2002;74:577-584.
32. Manabe S, Gu Z, Lipton SA. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2005;46:4747-4753.
33. Zhang X, Cheng M, Chintala SK. Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration. Invest Ophthalmol Vis Sci. 2004;45:2374-2383.
34. Sun MH, Chen KJ, Tsao YP, et al. Down-regulation of matrix metalloproteinase-9 by pyrrolidine dithiocarbamate prevented retinal ganglion cell death after transection of optic nerve in rats. Curr Eye Res. 2011;36:1053-1063.
35. Halfter W, Willem M, Mayer U. Basement membranedependent survival of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2005;46:1000-1009.
36. Hofmaier F, Hauck SM, Amann B, Degroote RL, Deeg CA. Changes in matrix metalloproteinase network in spontaneous autoimmune uveitis model. Invest Ophthalmol Vis Sci. 2011;52:2314-2320.
37. Ahmed F, Brown KM, Stephan DA, Morrison JC, Johnson EC, Tomarev SI. Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest Ophthalmol Vis Sci. 2004;45:1247-1258.
38. Guo Y, Cepurna WO, Dyck JA, Doser TA, Johnson EC, Morrison JC. Retinal cell responses to elevated intraocular pressure: a gene array comparison between the whole retina and retinal ganglion cell layer. Invest Ophthalmol Vis Sci. 2010;51:3003-3018.
39. Magnoni S, Baker A, Thomson S, et al. Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and-2 in ischemic brain injury. Gene Ther. 2007;14:621-625.
40. Tan HK, Heywood D, Ralph GS, Bienemann A, Baker AH, Uney JB. Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol Cell Neurosci. 2003; 22:98-106.
41. Kido N, Inatani M, Honjo M, et al. Dual effects of interleukin-1beta on N-methyl-D-aspartate-induced retinal neuronal death in rat eyes. Brain Res. 2001;910:153-162.
42. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 2002;297:1186-1190.
43. Agudo M, Perez-Marin MC, Lonngren U, et al. Time course profiling of the retinal transcriptome after optic nerve transection and optic nerve crush. Mol Vis. 2008;14:1050-1063.
44. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787-1794.
45. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res. 2008;173:409-421.
46. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci. 2006;26:12633-12641.
47. Chintala SK. The emerging role of proteases in retinal ganglion cell death. Exp Eye Res. 2006;82:5-12.
48. Kim EM, Hwang O. Role of matrix metalloproteinase-3 in neurodegeneration. J Neurochem. 2011;116:22-32.
49. Kim E-M, Shin E-J, Choi JH, et al. Matrix metalloproteinase-3 is increased and participates in neuronal apoptotic signaling downstream of caspase-12 during endoplasmic reticulum stress. J Biol Chem. 2010;285:16444-16452.
50. Gariano RF, Hu D, Helms J. Expression of angiogenesis-related genes during retinal development. Gene Expr Patterns. 2006; 6:187-192.
51. Takano A, Hirata A, Inomata Y, et al. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am J Ophthalmol. 2005;140: 654-660.
52. Sigal IA, Ethier CR. Biomechanics of the optic nerve head. Exp Eye Res. 2009;88:799-807.
53. Kirwan RP, Crean JK, Fenerty CH, Clark AF, O'Brien CJ. Effect of cyclical mechanical stretch and exogenous transforming growth factor-beta1 on matrix metalloproteinase-2 activity in lamina cribrosa cells from the human optic nerve head. J Glaucoma. 2004;13:327-334.
54. Akhter N, Nix M, Abdul Y, Singh S, Husain S. Delta-opioid receptors attenuate TNF-alpha-induced MMP-2 secretion from human ONH astrocytes. Invest Ophthalmol Vis Sci. 2013;54:6605-6611.
55. Dahlmann-Noor AH, Vijay S, Limb GA, Khaw PT. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov Today. 2010;15:287-299.
56. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Progr Retin Eye Res. 2000; 19:297-321.
57. Quill B, Docherty NG, Clark AF, O'Brien CJ. The effect of graded cyclic stretching on extracellular matrix-related gene expression profiles in cultured primary human lamina cribrosa cells. Invest Ophthalmol Vis Sci. 2011;52:1908-1915.
58. Morrison JC. Cepurna Ying Guo WO, Johnson EC. Pathophysiology of human glaucomatous optic nerve damage: insights from rodent models of glaucoma. Exp Eye Res. 2011; 93:156-164.
59. Zode GS, Sethi A, Brun-Zinkernagel AM, Chang IF, Clark AF, Wordinger RJ. Transforming growth factor-beta2 increases extracellular matrix proteins in optic nerve head cells via activation of the Smad signaling pathway. Mol Vis. 2011;17: 1745-1758.
60. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol. 2000;118:666-673.
61. Vos CM, Sjulson L, Nath A, et al. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol. 2000;163:324-330.
62. Johnson EC, Jia L, Cepurna WO, Doser TA, Morrison JC. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2007;48:3161-3177.
63. Agapova OA, Kaufman PL, Lucarelli MJ, Gabelt BT, Hernandez MR. Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. Brain Res. 2003;967:132-143.
64. Hughes PM, Wells GM, Perry VH, Brown MC, Miller KM. Comparison of matrix metalloproteinase expression during Wallerian degeneration in the central and peripheral nervous systems. Neuroscience. 2002;113:273-287.
65. Bull ND, Martin KR. Optic nerve restoration: new perspectives. J Glaucoma. 2007;16:506-511.
66. Yang P, Yang Z. Enhancing intrinsic growth capacity promotes adult CNS regeneration. J Neurol Sci. 2012;312: 1-6.
67. Goldberg JL, Barres BA. The relationship between neuronal survival and regeneration. Annu Rev Neurosci. 2000;23:579-612.
68. Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, Logan A. Matrix metalloproteases: degradation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons. Mol Cell Neurosci. 2005;28:64-78.
69. Pizzi MA, Crowe MJ. Matrix metalloproteinases and proteoglycans in axonal regeneration. Exp Neurol. 2007;204:496-511.
70. Muir EM, Adcock KH, Morgenstern DA, et al. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Molecular Brain Research. 2002;100:103-117.
71. Cua RC, Lau LW, Keough MB, Midha R, Apte SS, Yong VW. Overcoming neurite-inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix. Glia. 2013;61:972-984.
72. Ferguson TA, Muir D. MMP-2 and MMP-9 increase the neuritepromoting potential of schwann cell basal laminae and are upregulated in degenerated nerve. Mol Cell Neurosci. 2000; 16:157-167.
73. Chantry A, Gregson N, Glynn P. Degradation of myelin basic protein by a membrane-associated metalloprotease: neural distribution of the enzyme. Neurochem Res. 1992;17:861-867.
74. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res. 1993;36:432-440.
75. Zuo J, Ferguson TA, Hernandez YJ, Stetler-Stevenson WG, Muir D. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J Neurosci. 1998;18:5203-5211.
76. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol. 1999;11:614-621.
77. Duchossoy Y, Arnaud S, Feldblum S. Matrix metalloproteinases: potential therapeutic target in spinal cord injury. Clin Chem Lab Med. 2001;39:362-367.
78. Demestre M, Wells GM, Miller KM, et al. Characterisation of matrix metalloproteinases and the effects of a broadspectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience. 2004;124:767-779.
79. Charalambous P, Hurst LA, Thanos S. Engrafted chicken neural tube-derived stem cells support the innate propensity for axonal regeneration within the rat optic nerve. Invest Ophthalmol Vis Sci. 2008;49:3513-3524.
80. Pastrana E, Moreno-Flores MT, Gurzov EN, Avila J, Wandosell F, Diaz-Nido J. Genes associated with adult axon regeneration promoted by olfactory ensheathing cells: a new role for matrix metalloproteinase 2. J Neurosci. 2006;26:5347-5359.
81. Gaublomme D, Buyens T, De Groef L, et al. Matrix metalloproteinase 2 and membrane-type 1 matrix metalloproteinase co-regulate axonal outgrowth of mouse retinal ganglion cells. J Neurochem. In press.
82. Ahmed Z, Aslam M, Lorber B, Suggate EL, Berry M, Logan A. Optic nerve and vitreal inflammation are both RGC neuroprotective but only the latter is RGC axogenic. Neurobiol Dis. 2010;37:441-454.
83. Kurimoto T, Yin Y, Omura K, et al. Long-distance axon regeneration in the mature optic nerve: contributions of oncomodulin, cAMP, and pten gene deletion. J Neurosci. 2010;30:15654-15663.
84. Lorber B, Berry M, Douglas MR, Nakazawa T, Logan A. Activated retinal glia promote neurite outgrowth of retinal ganglion cells via apolipoprotein E. J Neurosci Res. 2009;87: 2645-2652.
85. Lorber B, Guidi A, Fawcett JW, Martin KR. Activated retinal glia mediated axon regeneration in experimental glaucoma. Neurobiol Dis. 2012;45:243-252.
86. Yin Y, Cui Q, Gilbert HY, et al. Oncomodulin links inflammation to optic nerve regeneration. Proc Natl Acad Sci U S A. 2009;106:19587-19592.
87. Jiang C, Klassen H, Zhang X, Young M. Laser injury promotes migration and integration of retinal progenitor cells into host retina. Mol Vis. 2010;16:983-990.
88. Johnson TV, Bull ND, Martin KR. Identification of barriers to retinal engraftment of transplanted stem cells. Invest Ophthalmol Vis Sci. 2010;51:960-970.
89. Kinouchi R, Takeda M, Yang L, et al. Robust neural integration from retinal transplants in mice deficient in GFAP and vimentin. Nat Neurosci. 2003;6:863-868.
90. Tucker B, Klassen H, Yang L, Chen DF, Young MJ, Elevated MMP. Expression in the MRL mouse retina creates a permissive environment for retinal regeneration. Invest Ophthalmol Vis Sci. 2008;49:1686-1695.
91. Suzuki T, Mandai M, Akimoto M, Yoshimura N, Takahashi M. The simultaneous treatment of MMP-2 stimulants in retinal transplantation enhances grafted cell migration into the host retina. Stem Cells. 2006;24:2406-2411.
92. Tucker BA, Redenti SM, Jiang C, et al. The use of progenitor cell/biodegradable MMP2-PLGA polymer constructs to enhance cellular integration and retinal repopulation. Biomaterials. 2009;31:9-19.
93. Yao J, Tucker BA, Zhang X, Checa-Casalengua P, Herrero-Vanrell R, Young MJ. Robust cell integration from cotransplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials. 2011;32:1041-1050.
94. Zhang Y, Klassen HJ, Tucker BA, Perez MT, Young MJ. CNS progenitor cells promote a permissive environment for neurite outgrowth via a matrix metalloproteinase-2-dependent mechanism. J Neurosci. 2007;27:4499-4506.
95. Bartsch U, Oriyakhel W, Kenna PF, et al. Retinal cells integrate into the outer nuclear layer and differentiate into mature photoreceptors after subretinal transplantation into adult mice. Exp Eye Res. 2008;86:691-700.
96. Klassen H, Kiilgaard JF, Zahir T, et al. Progenitor cells from the porcine neural retina express photoreceptor markers after transplantation to the subretinal space of allorecipients. Stem Cells. 2007;25:1222-1230.
97. Lamba DA, Gust J, Reh TA. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell. 2009;4: 73-79.
98. MacLaren RE, Pearson RA, MacNeil A, et al. Retinal repair by transplantation of photoreceptor precursors. Nature. 2006; 444:203-207.
99. Gonzalez-Cordero A, West EL, Pearson RA, et al. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat Biotech. 2013;31:741-747.
100. Bull ND, Irvine KA, Franklin RJ, Martin KR. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci. 2009;50: 4244-4253.
101. Bull ND, Limb GA, Martin KR. Human Müller stem cell (MIOM1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci. 2008;49:3449-3456.
102. Morrison CJ, Butler GS. RodrÃ-guez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009;21:645-653.